22/12/2020 - 18:24

PharmAust gains ethics approval to restart dog cancer trial

22/12/2020 - 18:24


Save articles for future reference.

ASX-listed oncology innovator, PharmAust, has received Government ethics approval to recommence a trial treating pet dogs suffering from cancer with its oral drug, Monepantel. PharmAust previously announced the first set of trial results had exceeded expectations by demonstrating that MPL tablets can make certain cancer lesions disappear and the recommencement of the trial is the next step on the pathway to commercialisation for the biotechnology specialist.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options